Whiteoak Capital Pharma & Healthcare Growth Direct Plan
SIP amount
Min. ₹100
Lumpsum amount
Min. ₹500

Whiteoak Capital Pharma & Healthcare Growth Direct Plan

NAV
₹14.5920
+0.34%
(12 Nov)
AUM
480 Cr
TER
0.66%
Risk
Very High Risk
Insights
Net Asset Value (NAV) is above its 200 days moving average
In beta. Send feedback here.
Compare with other fund
1Y
+10.6%
+7.2%
+6.0%
+5.8%
+1.0%
3Y
NA
+31.1%
+31.3%
+30.4%
+29.6%
5Y
NA
+31.6%
+27.5%
+33.0%
+30.6%
ALL
+23.7%
+17.2%
+18.2%
+12.3%
+16.1%
VOL
14.8%
19.7%
16.2%
20.1%
18.4%
TER
0.7%
0.9%
0.5%
0.8%
0.8%
AUM
₹480 Cr
₹1,418 Cr
₹7,766 Cr
₹5,714 Cr
₹1,054 Cr
INFO
1.60
0.88
1.12
0.61
0.87
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
Whiteoak Capital Pharma & Healthcare (G)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 31st Oct
Top holdings
Sun Pharmaceuticals Industries Ltd
7.8%
Divi's Laboratories Ltd
6.9%
J.B. Chemicals & Pharmaceuticals Ltd
6.5%
Fortis Healthcare Ltd
6.3%
Clearing Corporation Of India Ltd
5.5%
Laurus Labs Ltd
4.7%
Cipla Ltd
4.2%
Neuland Laboratories Ltd
3.8%
Lupin Ltd
3.7%
Sai Life Sciences Ltd
2.9%
Top industry exposure
Healthcare
87.7%
Basic Materials
3.2%
Other information
Minimum SIP
₹100
Minimum lumpsum
₹500
Additional lumpsum
₹500
Portfolio turnover
252%
Lock-in period
-
Exit load
• 1% for redemption within 30 days
Fund objective
The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. However, there can be no assurance that the investment objective of the Scheme will be realized.
Fund manager(s)
Piyush Baranwal
Ramesh Mantri
Trupti Agrawal
Dheeresh Pathak
Ashish Agrawal

FAQs